We analyzed tumor-infiltrating immune cells to investigate the mechanisms underlying the enhanced antitumor activity of combination treatment with TAS-115 and anti-PD-1 antibody (Fig. 5B–E). The gene discussed is PDCD1; the disease is neoplasm.